No download available

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

T. Bartosik - S.F. Seys - J. de Kinderen - M. Wagenmann - M. Bruch - A. Andrianakis - X. Gonzalez-Compta - V. Hox - L. Pardo Muñoz - S. Schneider - G. Bettio - M. Burian - J. Eckl-Dorna - M. Golet Fors - G. Mariën - C. Morgenstern - K. Scheckenbach - P-V. Tomazic - A. Tu - S. Allu - Z. Diamant - C. Bachert - I. Alobid - C. Cavaliere - W. Fokkens - P.W. Hellings - C. Hopkins - A. Izquierdo-Domínguez - X. Jaumont - A. Kjeldsen - A. Laulajainen-Hongisto - V. Lund - G. Mortuaire - P. Olsson - L. Van Gerven - S. Reitsma

DOI: 10.4193/Rhin25.514

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction
were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).

Rhinology 0 - 0: 0-0, 0000